Terms of Use

Vaccine Vision

Verndari was founded with the goal to eliminate needle phobia, and the need for the cold chain, with a cost-effective simple-to-use vaccination that can be mass produced. Verndari has developed a complete single-dose vaccination kit which includes VaxiPatch^TM. VaxiPatch is an “elegantly simple”...

Featured Article

Pharma company with UC Davis connection receives patent for painless vaccine technology Verndari Inc., a pharmaceutical company with laboratories at the UC Davis Medical Center, has received a patent for vaccines administered through adhesive skin patches. The technology, known as VaxiPatch, can be self-applied and is painless to the user, unlike typical vaccines that require a needle and syringe. The patent was issued to the company on July 17 and describes a method to manufacture the vaccine patches...

Featured Team Member

Durga Bobba
Member of the Board of Directors

Durga has over 25 years of global commercial biopharma experience. After an initial spell as a sales representative at Parke-Davis, he took on roles of increasing responsibility at major global pharmaceutical companies including Merck, Genentech and Amgen in the areas of Marketing, Product Development, Alliance Management and Business Development.

Durga started his 15-year career at Merck & Co, Inc. in pricing and then held U.S. and global roles that included U.S. brand management, business development and emerging markets. He ultimately joined the Vaccine Division as Sr. Director of International Commercial Operations and later Executive Director for the Eastern Europe Middle East and Africa region. Durga supported four ex-US launches and helped Merck Vaccines quadruple annual sales to $4 billion to become the world’s number one vaccine company. Durga is currently the Chief Business Officer of SutroVax.

Durga holds an MBA from Georgetown University where he received the Dean’s Citation for distinguished service and leadership.